These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 3924605)

  • 1. Protection against fatal Pseudomonas aeruginosa sepsis by immunization with smooth and rough lipopolysaccharides.
    Cryz SJ; Meadow PM; Fürer E; Germanier R
    Eur J Clin Microbiol; 1985 Apr; 4(2):180-5. PubMed ID: 3924605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide.
    Cryz SJ; Fürer E; Germanier R
    Infect Immun; 1984 Mar; 43(3):795-9. PubMed ID: 6698608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic activities of antibodies to the neutral-polysaccharide component of the Pseudomonas aeruginosa lipopolysaccharide are blocked by O side chains and mucoid exopolysaccharide (alginate).
    Hatano K; Goldberg JB; Pier GB
    Infect Immun; 1995 Jan; 63(1):21-6. PubMed ID: 7528730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
    Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR
    Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa.
    Priebe GP; Walsh RL; Cederroth TA; Kamei A; Coutinho-Sledge YS; Goldberg JB; Pier GB
    J Immunol; 2008 Oct; 181(7):4965-75. PubMed ID: 18802100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization.
    Lang AB; Fürer E; Senyk G; Larrick JW; Cryz SJ
    Hum Antibodies Hybridomas; 1990; 1(2):96-103. PubMed ID: 2129420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudomonas aeruginosa antigens as potential vaccines.
    Stanislavsky ES; Lam JS
    FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
    Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
    Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.
    Hemachandra S; Kamboj K; Copfer J; Pier G; Green LL; Schreiber JR
    Infect Immun; 2001 Apr; 69(4):2223-9. PubMed ID: 11254577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with Pseudomonas aeruginosa high-molecular-weight polysaccharides prevents death from Pseudomonas burn infections in mice.
    Pollack M; Pier GB; Prescott RK
    Infect Immun; 1984 Feb; 43(2):759-60. PubMed ID: 6420347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of cell wall Pseudomonas aeruginosa vaccines for protection against experimental pneumonia.
    Pennington JE; Pier GB
    Rev Infect Dis; 1983; 5 Suppl 5():S852-7. PubMed ID: 6419311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of a Protective Vaccine Against Lipopolysaccharide-Heterologous
    Liu C; Pan X; Xia B; Chen F; Jin Y; Bai F; Priebe G; Cheng Z; Jin S; Wu W
    Front Immunol; 2018; 9():1737. PubMed ID: 30093906
    [No Abstract]   [Full Text] [Related]  

  • 13. Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine.
    Cryz SJ; Furer E; Sadoff JC; Germanier R
    Infect Immun; 1986 Apr; 52(1):161-5. PubMed ID: 3082756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opsonic and protective activity of five human IgM monoclonal antibodies reactive with lipopolysaccharide antigen of Pseudomonas aeruginosa.
    Collins MS; Ladehoff DK; Mehton NS; Noonan JS
    FEMS Microbiol Immunol; 1990 Dec; 2(5-6):263-8. PubMed ID: 2127368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipopolysaccharide and high-molecular-weight polysaccharide serotypes of Pseudomonas aeruginosa.
    Pier GB; Thomas DM
    J Infect Dis; 1982 Feb; 145(2):217-23. PubMed ID: 6798136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cloning and surface expression of Pseudomonas aeruginosa O antigen in Escherichia coli.
    Goldberg JB; Hatano K; Meluleni GS; Pier GB
    Proc Natl Acad Sci U S A; 1992 Nov; 89(22):10716-20. PubMed ID: 1279692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific and non-specific mouse protection induced by different chemotypes of the Pseudomonas aeruginosa lipopolysaccharides.
    Stanislavsky ES; Makarenko TA; Kozhenova TE
    FEMS Microbiol Immunol; 1992 Oct; 5(4):181-9. PubMed ID: 1419116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-molecular-weight polysaccharide antigen from Pseudomonas aeruginosa immunotype 2.
    Pier GB; Sidberry HF; Sadoff JC
    Infect Immun; 1981 Nov; 34(2):461-8. PubMed ID: 6171520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model.
    Matthews-Greer JM; Gilleland HE
    J Infect Dis; 1987 Jun; 155(6):1282-91. PubMed ID: 3033095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide.
    Cryz SJ; Fürer E; Germanier R
    Infect Immun; 1983 Mar; 39(3):1072-9. PubMed ID: 6404817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.